595978 Disclosed are 3-(3-pentylphenyl)propionic acid derivatives as represented by the general formula (II), or a pharmaceutically acceptable salt thereof, wherein: n is 1； Q is C1-C4 alkyl optionally substituted with one Ra substituent； R1 is C5-C6 straight alkyl, C5-C6 straight alkenyl, C5-C6 straight alkynyl, or C5-C6 straight alkyl-Y-, R2 is hydrogen, halogen, haloalkyl, ORb, SRb, or NRcRd； R3 is H, halogen, haloalkyl, C1-C4 straight alkyl, ORb, SRb, or NRcRd； R4 is H, halogen, haloalkyl, C1-C4 straight alkyl, ORb, SRb, or NRcRd； R5 is H or ORb； Y is O, S, or NRcRd； Ra is ORb, SRb, or NRcRd； Rb is H or C1-C4 alkyl； and Rc and Rd are independently chosen from: H or C1-C4 alkyl. Also disclosed are compounds such as sodium (3-pentylphenyl)acetate, sodium 3-(3-pentylphenyl)propanoate, sodium 3-hydroxy-2-(3-pentylphenyl)propanoate, sodium 3-(3-butylphenyl)propanoate, sodium (3-hydroxy-5-pentylphenyl)acetate, sodium (2-hydroxy-5-pentylphenyl)acetate, sodium [3-(hexene-1-yl)phenyl]acetate and sodium (6-pentyl-pyridin-2-yl)acetate. Also disclosed is a pharmaceutical composition comprising a compound as defined above and a pharmaceutically acceptable carrier for preventing and/or treating a condition selected from the group consisting of (i) blood disorders (ii) renal disorders, nephropathies, and/or renal disorder complications； (iii) inflammatory-related diseases； and (iv) oxidative stress related disorders, including conditions / diseases such as anemia, neutropenia, arthritis, systemic lupus erythematosus (SLE), ITP, glomerulonephritis, vasculitis, psoriatic arthritis, psoriasis, Crohn's disease, inflammatory bowel disease, ankylosing spondylitis, Sjögren's syndrome, Still's disease, uveitis, scleroderma, myositis, Reiter's syndrome, Wegener's syndrome, cardiovascular diseases, cancer, diabetes, arthritis, atherosclerosis, Parkinson's disease, heart failure, myocardial infarction, Alzheimer's disease, chronic fatigue syndrome and autoimmune diseases.
